OTCMKTS:KHTRF Knight Therapeutics (KHTRF) Stock Price, News & Analysis $7.18 0.00 (0.00%) As of 09/23/2026 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Knight Therapeutics Stock (OTCMKTS:KHTRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's Range$7.18▼$7.1850-Day Range$6.60▼$7.2552-Week Range$4.07▼$7.40Volume4,200 shsAverage Volume7,861 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Knight Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative medicines. The company concentrates on therapies that address unmet medical needs, including specialty, orphan and hospital-based treatments. Through licensing and commercialization agreements, Knight offers a portfolio of prescription products across therapeutic areas such as oncology, rare diseases, infectious diseases and neurology. Its activities include securing regulatory approvals, introducing products to healthcare professionals and supporting the distribution of medicines in the markets it serves. Founded in 2014 by Jonathan Goodman, Knight is headquartered in Montreal, Quebec. The company has built operations in Canada and Latin America, with activities conducted through regional subsidiaries and commercial partnerships. Samira Sakhia serves as the company's president and chief executive officer, while Jonathan Goodman is executive chairman.AI Generated. May Contain Errors. Read More Receive KHTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KHTRF Stock News HeadlinesKnight Therapeutics Announces Regulatory Submission of GEMTESA® in CanadaSeptember 15, 2026 | financialpost.comFKnight Therapeutics Announces Regulatory Submission of GEMTESA® in CanadaSeptember 15, 2026 | globenewswire.comAI’s biggest bottleneck could mean double digit gains in 21 daysTradeSmith's AI forecasting tool just flagged a stock for its September rotation sitting in the energy sector, up nearly 50 percent this year. Hyperscalers have committed 1 trillion dollars to data center buildouts, and a single facility can use as much power as a city the size of Pittsburgh. TradeSmith built its model on TimeGPT, a system pioneered at Google, scanning hundreds of billions of data points daily to surface opportunities like this.September 24 at 1:00 AM | TradeSmith (Ad)Knight Therapeutics Inc KHTRFSeptember 10, 2026 | morningstar.comMKnight Therapeutics Announces Regulatory Approval of TAVALISSE® in ColombiaSeptember 1, 2026 | financialpost.comFKnight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in BrazilAugust 27, 2026 | financialpost.comFKnight Therapeutics Announces Launch of WYNZORA® in CanadaAugust 20, 2026 | financialpost.comFRBC Capital Remains a Buy on Knight Therapeutics (KHTRF)August 8, 2026 | theglobeandmail.comSee More Headlines KHTRF Stock Analysis - Frequently Asked Questions How have KHTRF shares performed this year? Knight Therapeutics' stock was trading at $4.3765 at the beginning of 2026. Since then, KHTRF stock has increased by 64.1% and is now trading at $7.18. How do I buy shares of Knight Therapeutics? Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/24/2026Next Earnings (Estimated)11/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:KHTRF CIKN/A Webwww.gud-knight.com Phone(514) 484-4483FaxN/AEmployees725Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:KHTRF) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
